T. Rowe Price Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

T. Rowe Price Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-868,006	Closed	-$93.2M	–	593
2023 Q1	$93.2M	Buy	868,006 +3,467	+0.4%	+$399K	0.07%	270
2022 Q4	$95.1M	Buy	864,539 +457,288	+112%	+$29.7M	0.07%	266
2022 Q3	$24M	Buy	+407,251	New	+$18.6M	0.02%	431

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

T. Rowe Price Investment Management's RXDX Position: Q2 2023 in Review

T. Rowe Price Investment Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 868,006 shares — an estimated $93.2M sold.

T. Rowe Price Investment Management first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $95.1M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

T. Rowe Price Investment Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Investment Management sold 868,006 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $93.2M.
T. Rowe Price Investment Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
T. Rowe Price Investment Management's Prometheus Biosciences, Inc. Common Stock position peaked at $95.1M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.